128 related articles for article (PubMed ID: 7992097)
1. Use of interferon in the treatment of chronic myelogenous leukemia.
Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):3-7. PubMed ID: 7992097
[TBL] [Abstract][Full Text] [Related]
2. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Gutterman J
Oncology (Williston Park); 1987 Sep; 1(7):35-40, 48-9, 52. PubMed ID: 3152810
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
7. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
[TBL] [Abstract][Full Text] [Related]
9. [Interferon-alpha in chronic myeloid leukemia].
Hehlmann R
Fortschr Med; 1997 Mar; 115(9):30-4, 37-8. PubMed ID: 9206694
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
[TBL] [Abstract][Full Text] [Related]
11. [Interferon therapy for chronic myelogenous leukemia].
Shibata A; Hashimoto S
Gan To Kagaku Ryoho; 1993 Feb; 20(2):200-6. PubMed ID: 8434957
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
13. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
[TBL] [Abstract][Full Text] [Related]
14. [Chronic myeloid leukemia].
Hehlmann R
Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
[TBL] [Abstract][Full Text] [Related]
15. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
16. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
[TBL] [Abstract][Full Text] [Related]
17. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith TL; Rios MB; Kantarjian H
Clin Cancer Res; 2000 Jan; 6(1):147-52. PubMed ID: 10656443
[TBL] [Abstract][Full Text] [Related]
18. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
19. [Recent progress in therapy for chronic myelogenous leukemia].
Urabe A
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
[TBL] [Abstract][Full Text] [Related]
20. New perspectives with interferon alpha. The German CML study group experience.
Hehlmann R; Ansari H; Adelberger V; Heinze B; Hossfeld K; Hochhaus A; Heimpel H
Bone Marrow Transplant; 1994; 14 Suppl 3():S14-20. PubMed ID: 7697004
[No Abstract] [Full Text] [Related]
[Next] [New Search]